The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls

Neuropsychopharmacology

Volumn 33, Issue 3, 2008, Pages 480-490

  Barr, Ruth S ^a,b   Culhane, Melissa A ^a   Jubelt, Lindsay E ^a   Mufti, Rana S ^a,b   Dyer, Michael A ^a   Weiss, Anthony P ^a,b   Deckersbach, Thilo ^a,b   Kelly, John F ^a,b   Freudenreich, Oliver ^a,b   Goff, Donald C ^a,b   Evins, A Eden ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Schizophrenia Program

Author keywords

Attention; Cognition; Nicotine; Nonsmokers; Schizophrenia; Smoking

Indexed keywords

NICOTINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADMINISTRATION, CUTANEOUS; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINE; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIC PSYCHOLOGY;

EID: 38149062692     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301423     Document Type: Article

References (86)

1. Addy NA, Pocivavsek A, Levin ED (2005). Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology 30: 1121-1127.
2. Adler LE, Hoffer LD, Wiser A, Freedman R (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861.
3. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32: 607-616.
4. Andreasen NC (1981). Scale for the Assessment of Negative Symptoms (SANS). University of Iowa: Iowa City.
5. Aron AR, Poldrack RA (2005). The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/ hyperactivity disorder. Biol Psychiatry 57: 1285-1292.
6. Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK (2003). Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 28: 2184-2191.
7. Badcock JC, Michie PT, Johnson L, Combrinck J (2002). Acts of control in schizophrenia: dissociating the components of inhibition. Psychol Med 32: 287-297.
8. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM et al (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351-364.
9. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS (1979). Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205: 929-932.
10. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L (1989). The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 29: 65-85.
11. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L (1988). The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 26: 223-238.
12. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59: 898-907.
13. Dalack GW, Healy DJ, Meador-Woodruff JH (1998). Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155: 1490-1501.
14. Dawkins L, Powell JH, West R, Powell J, Pickering A (2007). A double-blind placebo-controlled experimental study of nicotine: II-Effects on response inhibition and executive functioning. Psychopharmacology (Berl) 190: 457-467.
15. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L (2002). Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 56: 47-54.
16. Depatie L, O'Driscoll GA, Holahan AL, Atkinson V, Thavundayil JX, Kin NN et al (2002). Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, crossover study. Neuropsychopharmacology 27: 1056-1070.
17. Dolan SL, Sacco KA, Termine A, Seyal AA, Dudas MM, Vessicchio JC et al (2004). Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res 70: 263-275.
18. Durany N, Zochling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T et al (2000). Human post-mortem striatal alpha4-beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 287: 109-112.
19. Ernst M, Heishman SJ, Spurgeon L, London ED (2001). Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology 25: 313-319.
20. Evins AE, Culhane MA, Deckersbach T, Cather C, Freudenreich O, Henderson DC et al (2005a). Predictors of Smoking Cessation in Patients with Schizophrenia. 11th Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
21. Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC et al (2005b). Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 66: 1184-1190.
22. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute: New York.
23. Foulds J, Stapleton J, Swettenham J, Bell N, McSorley K, Russell MA (1996). Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology (Berl) 127: 31-38.
24. Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM et al (1994). Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 2: 179-192.
25. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587-592.
26. Freedman R, Hall M, Adler LE, Leonard S (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22-33.
27. George TP, Verrico CD, Picciotto MR, Roth RH (2000). Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 295: 58-66.
28. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT et al (2002). Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26: 75-85.
29. Glassman AH (1993). Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150: 546-553.
30. Goff DC, Henderson DC, Amico E (1992). Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194.
31. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger D (1997). Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54: 159-165.
32. Golden CJ, Freshwater SM (1998). The Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Stoelting Co.: Wood Dale, IL.
33. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
34. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26: 119-136.
35. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B et al (2004). Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29: 1378-1385.
36. Heishman SJ, Henningfield JE (2000). Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers. Psychopharmacology (Berl) 152: 321-333.
37. Heishman SJ, Snyder FR, Henningfield JE (1993). Performance, subjective, and physiological effects of nicotine in non-smokers. Drug Alcohol Depend 34: 11-18.
38. Henik A, Carter CS, Salo R, Chaderjian M, Kraft L, Nordahl TE et al (2002). Attentional control and word inhibition in schizophrenia. Psychiatry Res 110: 137-149.
39. Hennings EC, Kiss JP, Vizi ES (1997). Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res 759: 292-294.
40. Hershman KM, Freedman R, Bickford PC (1995). GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus. Neurosci Lett 190: 133-136.
41. Hughes J (1986). Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-997.
42. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004). Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 55: 850-858.
43. Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 146: 373-390.
44. Kay SR (1991). Positive and Negative Syndromes in Schizophrenia. Brunner/Mazel: New York.
45. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000). The effects of nicotine on Parkinson's disease. Brain Cogn 43: 274-282.
46. Kumari V, Postma P (2005). Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29: 1021-1034.
47. Kumari V, Soni W, Sharma T (2001). Influence of cigarette smoking on prepulse inhibition of acoustic startle response in schizophrenia. Hum Psychopharmacol 16: 321-326.
48. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE et al (1998). The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121(Pt 7): 1343-1355.
49. Le Houezec J, Halliday R, Benowitz NL, Callaway E, Naylor H, Herzig K (1994). A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology (Berl) 114: 628-634.
50. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W et al (1996). Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431-445.
51. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M et al (2002). Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59: 1085-1096.
52. Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J et al (1998). Transdermal nicotine effects on attention. Psychopharmacology (Berl) 140: 135-141.
53. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH et al (1996a). Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 123: 55-63.
54. Levin ED, Wilson W, Rose JE, McEvoy J (1996b). Nicotinehaloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15: 429-436.
55. Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB (2006). Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl) 184: 292-305.
56. Marder SR, Fenton W (2004). Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5-9.
57. Marder SR, Fenton W, Youens K (2004). Schizophrenia, IX: Cognition in schizophrenia - the MATRICS initiative. Am J Psychiatry 161: 25.
58. Martin LF, Kem WR, Freedman R (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174: 54-64.
59. McEvoy JP, Freudenreich O, Wilson WH (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46: 125-129.
60. McGehee D, Heath M, Gelber S, Devay P, Role W (1995). Nicotine enhancement of fast excitatory synaptic transmission in the CNS by presynaptic receptors. Science 269: 1692-1696.
61. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999). Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 146: 162-174.
62. Mumenthaler MS, Yesavage JA, Taylor JL, O'Hara R, Friedman L, Lee H et al (2003). Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 28: 1366-1373.
63. Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA et al (2004). Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 174: 334-340.
64. Newhouse PA, Potter A, Singh A (2004). Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36-46.
65. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
66. Olincy A, Johnson LL, Ross RG (2003). Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 117: 223-236.
67. Olincy A, Ross R, Young D, Roath M, Freedman R (1998). Improvement in smooth pursuit eye movement after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 18: 175-185.
68. Picciotto MR, Caldarone BJ, King SL, Zachariou V (2000). Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22: 451-465.
69. Postma P, Gray JA, Sharma T, Geyer M, Mehrotra R, Das M et al (2006). A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) 184: 589-599.
70. Rezvani AH, Kholdebarin E, Dawson E, Levin ED (2007). Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int J Neuropsychopharmacol 1-8. Print copy in press (originally published online February 13, 2003 at http://journals. cambridge. org/action/displayJournal?jid=PNP).
71. Roberts RJ, Pennington BF (1996). An interactive framework for examining preforontal cognitive processes. Dev Neurosychol 12: 105-126.
72. Sacco KA, Bannon KL, George TP (2004). Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 18: 457-474.
73. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S et al (2005). Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62: 649-659.
74. Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK (2002). The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 52: 721-728.
75. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK (1991). The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 6: 95-102.
76. Slemmer JE, Martin BR, Damaj MI (2000). Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
77. Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27: 479-497.
78. Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S et al (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31: 637-643.
79. Symonds CS, Gallagher P, Thompson JM, Young AH (2004). Effects of the menstrual cycle on mood, neurocognitive and neuroendocrine function in healthy premenopausal women. Psychol Med 34: 93-102.
80. Vink M, Ramsey NF, Raemaekers M, Kahn RS (2006). Striatal dysfunction in schizophrenia and unaffected relatives. Biol Psychiatry 60: 32-39.
81. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569.
82. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS et al (1998). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 155: 344-349.
83. Wechsler D (1997b). Wechsler Memory Scale - Third edition: Administration and Scoring Manual. Psychological Corporation: San Antonio, TX.
84. Weiss AP, Jubelt LE, Barr RS, Goff DC, Rigotti NA, Evins AE (2006). The Effect of Transdermal Nicotine on Episodic Memory Performance in Nonsmoking Patients with Schizophrenia. Neuropsychopharmacology 31: S112-113.
85. White HK, Levin ED (1999). Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 143: 158-165.
86. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000). Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393: 51-58.